Asthma Paid Clinical Trials in Pennsylvania

Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.

The primary aim of this clinical trial is to study the potential effectiveness of an investigational drug in treating severe eosinophilic asthma, characterized by persistent symptoms and frequent flare-ups despite regular asthma medication. Secondary goals of this study include evaluating the safety and tolerability aspects of the investigational drug. To maintain objectivity, participants are randomly assigned into groups, receiving either the actual drug or a placebo. The outcome of this research will be instrumental in determining if the investigational drug stands as a possible treatment for those grappling with severe eosinophilic asthma. If you are interested in applying for this study, initiating contact will lead to direct engagement from the research site. They will provide more information on the study and answer any questions related to participation requirements, the potential risks and benefits, and any compensation on offer.

The main objectives of this study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe atopic dermatitis, commonly known as eczema. The study aims to understand how different dosages of the investigational medication affect eczema flare ups. Participants will be randomly assigned to receive various dosages of the investigational medication or a placebo. Should you express interest, you will be contacted directly by the research site, who will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.

Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.

Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.